RecruitingPHASE1, PHASE2NCT05127226
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
Studying Angelman syndrome due to a point mutation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Intervention
- ION582(drug)
- Enrollment
- 70 enrolled
- Eligibility
- 0-50 years · All sexes
- Timeline
- 2021 – 2029
Study locations (11)
- Rady Children's Hospital, San Diego, California, United States
- Colorado Children's Hospital Research Institute, Aurora, Colorado, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of North Carolina at Chapel Hill School of Medicine, Carrboro, North Carolina, United States
- Texas Children's Hospital, Houston, Texas, United States
- Sydney Children's Hospital, Kids Cancer Centre, Randwick, Australia
- Necker-Enfants Malades Hospital, Paris, France
- Sheba Medical Center, Ramat Gan, Israel
- Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
- STRONG Group University of Oxford, Oxford, Oxfordshire, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05127226 on ClinicalTrials.govOther trials for Angelman syndrome due to a point mutation
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07417137A Natural History Study of Angelman SyndromeMassachusetts General Hospital
- RECRUITINGPHASE1, PHASE2NCT07181837A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman SyndromeMavriX Bio, LLC
- RECRUITINGPHASE2NCT07157254A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)Ultragenyx Pharmaceutical Inc
- RECRUITINGNCT06737718Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman SyndromeAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE3NCT06617429Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)Ultragenyx Pharmaceutical Inc
- ENROLLING BY INVITATIONPHASE3NCT06415344Long-term Extension of GTX-102 in Angelman SyndromeUltragenyx Pharmaceutical Inc
- RECRUITINGNCT06229769Natural History Study for Patients With Angelman SyndromeCentre Hospitalier Universitaire de Liege
- RECRUITINGNCT05293184The Global Angelman Syndrome RegistryFoundation for Angelman Syndrome Therapeutics, Australia
See all trials for Angelman syndrome due to a point mutation →